Are you still recommending autologous stem cell transplantation (ASCT) for all eligible myeloma patients who achieve remission after induction with a quadruplet regimen?

Our institution still recommends upfront autologous transplant for most fit patients. We appreciate the recent results from CEPHEUS and BENEFIT, but if we believe that achieving MRD negativity is important, the addition of autologous transplant improves the rate of MRD negativity, which ultimately s...

No. ASCT is a discussion process with the patients. The GRIFFIN and PERSEUS trials used Dara throughout induction, consolidation, and maintenance. The MRD- status deepened over the course of the treatment. The IFM-09 and DETERMINATION trials showed similar OS for patients with upfront vs delayed ASC...